Reddy's may launch 3-4 generics in US

The likely products are nefazodone, isotretinoin and ciprofloxacin. According to G V Prasad, the chief executive officer (CEO), the company would launch another 4-6 generic products in US during the next fiscal.

"Our aim is to become one of the top ten US generic companies by targetting unique high-value opportunities. To make this possible, we are increasing our portfolio of high-margin products and being in the first wave of product launches," he said in the latest annual report.

The company has touched sales of nearly $100 million three years after entering into the UK & US generics market.

The company also exports branded formulations to Russia, Mexico and China, which are semi-regulated markets.

During the first quarter of the current fiscal, it recorded a sales of Rs 119.8 crore in the generics segment.

"We are also building a commercial front-end in US and UK, and exploring opportunities in Canada and other countries in Europe. We have succeeded in establishing a presence in the US with fluoxetine and more recently with ibuprofen. Amolodipine maleate (whose launch depends on the US Federal Circuit Court's decision on an appeal filed by Pfizer against district court's decision favouring Dr Reddy's), our first speciality product, can only further consolidate this equity," Prasad added.

Dr Reddy's existing generic product portfolio consists of a total number of seven drugs covering 15 dosage strengths.

These are ranitidine, famotidine, oxaprozin, fluoxetine, enlapril maleate plus hydrochloro thiazide (combination), tizanidine hydrochloride and ibuprofen.

During the first quarter of the current fiscal, Dr Reddy's filed 1 abbreviated new drug application with Para IV certification, taking the total to 35.

Of these, 24 are pending approval with US Food and Drug Administration.

Its generic pipeline addresses a market size of $19 billion based on innovators branded sales last year.

Dr Reddy's recorded a sales of Rs 119.8 crore in the generics segment in the first quarter. It plans to launch more generic products in UK, which has contributed Rs 22 crore to the sales in the first quarter.